First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: PIK3CA Mutation|Solid Tumor, Adult|HER2-negative Breast Cancer|Breast Cancer|Metastatic Breast Cancer|Advanced Breast Cancer|Unresectable Solid Tumor
Interventions: DRUG: RLY-2608|DRUG: Fulvestrant|DRUG: Palbociclib 125mg|DRUG: Ribociclib 400mg|DRUG: Ribociclib 600mg
Sponsor: Relay Therapeutics, Inc.